Lympathic Mapping with SPECT-CT guided Radiotherapy for Oropharyngeal Cancer
Study Summary
This trialis testing if using imaging to guide radiation therapy to one side of the neck can reduce risk of cancer returning or spreading.
- Oropharyngeal Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 13 Secondary · Reporting Duration: 8 years
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
Bilateral Neck Radiotherapy
1 of 2
Lympathic Mapping with SPECT-CT guided Radiotherapy
1 of 2
Active Control
Experimental Treatment
510 Total Participants · 2 Treatment Groups
Primary Treatment: Lympathic Mapping with SPECT-CT guided Radiotherapy · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 13 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has the FDA issued authorization for Lympathic Mapping with SPECT-CT guided Radiotherapy?
"There is prior clinical evidence that supports the saftey of Lympathic Mapping with SPECT-CT guided Radiotherapy, thus it was rated a 3 on our scale." - Anonymous Online Contributor
What is the enrollment size of this experiment?
"Affirmative. Clinicaltrials.gov has information that this research is currently recruiting, having been posted on September 29th 2022 and updated as recently as February 3rd 2023. The medical experiment seeks to enrol 510 participants from a single site." - Anonymous Online Contributor
Is enrollment into this experiment currently open to participants?
"Affirmative. As denoted on clinicaltrials.gov, this research was first made public in September 2022 and recently updated in February 2023. The study is enrolling 510 volunteers at a single site." - Anonymous Online Contributor